Sage strategy for postpartum depression drug Zulresso keys on patient support

Postpartum depression is complex—and so is the first FDA-approved treatment. The 60-hour inpatient infusion process for Sage Therapeutic’s Zulresso calls for more-than-typical information and education, so along with identifying appropriate healthcare facilities, Sage has created a national support center to help patients through the process.